Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240747 · ClinicalTrials.gov registry record · Phase 3
Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00240747: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00240747 is a Phase 3 study that was terminated before completion, run by Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00240747, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric patients.
Interventions
- DRUG Synercid
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
Why NCT00240747 stopped before completion
NCT00240747 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Synercid is the first listed.
NCT00240747 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00240747 about?
NCT00240747 is a clinical study titled "Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients". Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric...
What is the current status of trial NCT00240747?
This trial is currently terminated. It is a Phase 3 study. The study started on 2000-06. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00240747?
The interventions under investigation include: Synercid (DRUG).
Who is sponsoring clinical trial NCT00240747?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia